Skip to main content
. 2023 Dec 13;14:1234869. doi: 10.3389/fimmu.2023.1234869

Figure 3.

Figure 3

The impact of cladribine (CLA) treatment on miRNA profiles. (A) Volcano plot of the CLA T1 (n = 10) vs. pre-CLA (n = 10) miRNAs. (B) Multidimensional scaling of CLA samples based on the miRNA profiles. Each arrow corresponds to a different patient treated with CLA and connects the miRNA profile at T0 (light purple dot) to the profile at T1 (dark purple dot). (C) Levels of differentially expressed (DE) miRNAs in CLA T1 vs. pre-CLA. Log2 median normalized values of DE miRNA are shown. The CLA T1 samples correspond to subjects with relapsing–remitting multiple sclerosis, whose miRNA levels were analyzed 6 months after CLA treatment initiation. miRNAs were selected using R limma test false discovery rate <0.05 + linear |fold change| >1.5 thresholds. The boxes correspond to median ± interquartile range, and the black dots are outliers.